TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01801189

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin
Description: One 300 mg oral dose of Pregabalin given before surgery.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for Pregabalin)
Description: One oral dose of placebo given before surgery.
Study: NCT02021071

Intervention type: RADIATION
Intervention: XperGuide
Description: Live 3D image needle guidance which overlays live fluoroscopy and 3D soft tissue imaging data from previous acquired CT, MR or XperCT.

Intervention type: RADIATION
Intervention: XperGuide with virtual path planning
Description: Instrument guidance allowing certain tasks that would normally occur using continuous X-ray guidance to be performed with reduced dose for patient and staff.
Study: NCT00626834

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vigabatrin
Description: Dose 1 BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vigabatrin
Description: Dose 2 BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vigabatrin
Description: Dose 3 BID

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching placebo
Description: Matching placebo BID
Study: NCT04401410

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dose Finding Phase (MTD)
Description: Enrollment to the dose escalation phase will be staggered. The first patient enrolled on each of the 3 dose levels (DL1, DL2 and DL3) will have to complete the 14-day toxicity monitoring window prior to enrollment of the next patients. Prior to dose escalation, all patients at a particular dose level should have completed the minimum 14-day toxicity monitoring window before enrolling to a higher dose level.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Partially HLA-matched SARS-CoVSTs
Description: Infusion of SARS-CoVSTs at the MTD level as determined in the Dose Finding Phase

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine care (no SARS-CoVSTs)
Description: Patients receive routine care for COVID19 per institutional standards (including antivirals such as remdesivir or other FDA-EUA approved products and thromboprophylaxis).
Study: NCT04511338

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dialyzer with Endexo
Description: Sequence AB:~Period 1 Circuit A (Five Visits: 1,2,3,4,5) Period 2 Circuit B (Five Visits: 9,10,11,12,13)~Sequence BA:~Period 1 Circuit B (Five Visits: 1,2,3,4,5) Period 2 Circuit A (Five Visits: 9,10,11,12,13)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dialyzer with Endexo
Description: Sequence AB:~Period 1 Circuit A (Five Visits: 1,2,3,4,5) Period 2 Circuit B (Five Visits: 9,10,11,12,13)~Sequence BA:~Period 1 Circuit B (Five Visits: 1,2,3,4,5) Period 2 Circuit A (Five Visits: 9,10,11,12,13)
Study: NCT01555736

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: grass (80%) and rye (20%) pollens allergoids
Description: comparison of two schemes of immunotherapy - preseasonal and perennial immunotherapy.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: grass (80%) and rye (20%) pollens allergoids
Description: comparison of two schemes of immunotherapy - preseasonal and perennial immunotherapy.
Study: NCT00774956

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Exercise training program
Description: A 6 week shoulder exercise training program

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Exercise training program
Description: A 6 week shoulder exercise training program
Study: NCT02211950

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 44847

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 44847

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 44847

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 44847

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 44847

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acarbose

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Japanese diet
Study: NCT02288442

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise
Description: Exercise training for 8 weeks (aerobic exercise, resistance training and inspiratory muscle training thrice a week)
Study: NCT00651768

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: budesonide/formoterol

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Symbicort pMDI + budesonide HFA pMDI
Description: Symbicort 2 X 160/4.5mcg \& budesonide HFA pMDI 4 X 160mcg
Study: NCT01706991

Intervention type: DEVICE
Intervention: Pediatric Vision Scanner eye scan
Description: Subject is scanned with a 2.5 second pediatric vision scanner device test.
Study: NCT02281292

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Sham injection
Description: Mock injection administered as an empty hub without needle

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Sham injection
Description: Mock injection administered as an empty hub without needle
Study: NCT04067986

Intervention type: DRUG
Group type: OTHER
Intervention: Camrelizumab
Description: Camrelizumab One course will last 28 days.Intravenous injection at a dose of 200 mg, q2w~One course will last 28 days. Oral administration at a dose of 250 mg/d

Intervention type: DRUG
Group type: OTHER
Intervention: Apatinib
Description: Apatinib One course will last 28 days.Oral administration at a dose of 250 mg, qd
Study: NCT01706991

Intervention type: DEVICE
Intervention: Pediatric Vision Scanner eye scan
Description: Subject is scanned with a 2.5 second pediatric vision scanner device test.

Intervention type: DEVICE
Intervention: Pediatric Vision Scanner eye scan
Description: Subject is scanned with a 2.5 second pediatric vision scanner device test.
Study: NCT00986804

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Study: NCT02114060

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GEN-003 Vaccine (30μg of each antigen)
Description: HSV-2 protein subunit vaccine consisting of 2 recombinant T cell antigens: internal fragment of the immediate early (IE) protein ICP and glycoprotein D

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GEN-003 Vaccine (30μg of each antigen)
Description: HSV-2 protein subunit vaccine consisting of 2 recombinant T cell antigens: internal fragment of the immediate early (IE) protein ICP and glycoprotein D

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GEN-003 Vaccine (30μg of each antigen)
Description: HSV-2 protein subunit vaccine consisting of 2 recombinant T cell antigens: internal fragment of the immediate early (IE) protein ICP and glycoprotein D

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GEN-003 Vaccine (60μg of each antigen)
Description: HSV-2 protein subunit vaccine consisting of 2 recombinant T cell antigens: internal fragment of the immediate early (IE) protein ICP and glycoprotein D

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GEN-003 Vaccine (60μg of each antigen)
Description: HSV-2 protein subunit vaccine consisting of 2 recombinant T cell antigens: internal fragment of the immediate early (IE) protein ICP and glycoprotein D

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GEN-003 Vaccine (60μg of each antigen)
Description: HSV-2 protein subunit vaccine consisting of 2 recombinant T cell antigens: internal fragment of the immediate early (IE) protein ICP and glycoprotein D

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Matrix-M2 Adjuvant (25μg)
Description: Matrix-M2 is derived from fractionated Quillaja saponins, phosphatidylcholine, and cholesterol.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Matrix-M2 Adjuvant (25μg)
Description: Matrix-M2 is derived from fractionated Quillaja saponins, phosphatidylcholine, and cholesterol.
Study: NCT01328665

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Expressive Writing
Description: Writing intervention for cognitive appraisal of stressor.
Study: NCT01397643

Intervention type: OTHER
Group type: OTHER
Intervention: Non-operative
Description: Patients in the non-operative arm will be managed conservatively using a sling, or an above elbow lightweight cast if problems with pain, for 10-14 days post injury. Patients will then be allowed to mobilise as able.

Intervention type: OTHER
Group type: OTHER
Intervention: Operative
Description: For those patients in the operative group, tension band wire of plate fixation will be employed depending on the choice of their supervising consultant. Following surgery, the post-operative assessment and course will be as per normal protocol for patients who are not in this study. Patients in the operative group will be immobilised depending on fracture fixation during surgery and the decision will be made by the treating surgeon. Physiotherapy will be arranged when required.
Study: NCT00749021

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranibizumab
Description: 0.5 mg of intravitreal ranibizumab monthly for 12 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranibizumab
Description: 0.5 mg intravitreal injection of ranibizumab for 4 months followed by PRN dosing

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranibizumab
Description: 2.0mg of intravitreal ranibizumab monthly for 12 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranibizumab
Description: 2.0mg of intravitreal injection of Ranibizumab for 4 months followed by PRN dosing
Study: NCT04810130

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Soccer Kicking
Description: Subjects assigned to the soccer kicking arm will complete 10 soccer kicks in 10 minutes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Soccer Heading (Frontal)
Description: Subjects assigned to the soccer heading (frontal) arm will complete 10 frontal soccer headers (ball headed directly back to launch direction) in 10 minutes. Soccer balls will be projected at 10-17.5 m/s from approximately 10-15 m with a JUGS ball launcher.
Study: NCT02114060

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Matrix-M2 Adjuvant (50μg)
Description: Matrix-M2 is derived from fractionated Quillaja saponins, phosphatidylcholine, and cholesterol.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Matrix-M2 Adjuvant (50μg)
Description: Matrix-M2 is derived from fractionated Quillaja saponins, phosphatidylcholine, and cholesterol.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Matrix-M2 Adjuvant (75μg)
Description: Matrix-M2 is derived from fractionated Quillaja saponins, phosphatidylcholine, and cholesterol.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Matrix-M2 Adjuvant (75μg)
Description: Matrix-M2 is derived from fractionated Quillaja saponins, phosphatidylcholine, and cholesterol.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% Normal Saline (NaCl)
Study: NCT04414488

Intervention type: PROCEDURE
Intervention: Thoracic paravertebral block (ThPVB)
Description: Before the induction of general anaesthesia a single-shot ThPVB was performed at the Th3 to Th4 level, approximately, 2.5 to 3 cm lateral to tip of a spinous process. A preblock ultrasound examination was undertaken to assess the depth of the transverse process and the pleura. An insulated 10 cm long needle was used and this was connected to a peripheral nerve stimulator with a set current of 2.5 milliampere(mA). The current was gradually reduced as the needle was inserted until the appearance of visible intercostal muscles activity with a current of 0.3 to 0.5mA (paravertebral space identification). Plain bupivacaine (0.3 ml\*kg-1) was then injected after a negative aspiration test for air or blood. The efficacy of the blockade to cold was checked after 20 min with a plastic ampoule of saline kept in the freezer. Testing was symmetrical on both sides of thorax. A difference in sensation to cold between the blocked and unblocked sides was taken to indicate an effective block.
Study: NCT04810130

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Soccer Heading (Oblique)
Description: Subjects assigned to the soccer heading (oblique) arm will complete 10 oblique soccer headers (ball headed 90° to the right from ball launch direction) in 10 minutes. Soccer balls will be projected at 10-17.5 m/s from approximately 10-15 m with a JUGS ball launcher.
Study: NCT01607307

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral/enteral TJ-100 solution
Description: Oral TJ-100 solution (5 g tid, 15 g/day) given immediately before meals or every 8 h from preoperative day 3 to postoperative day 7 for 10 consecutive days. A diluent TJ-100 solution given immediately after surgery and on postoperative day 1 via Argyle enteral feeding tube (10 Fr), which terminates in the jejunum to prevent aspiration pneumonia.
Study: NCT01300767

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lotrafilcon B contact lens (AIR OPTIX® AQUA)
Description: Silicone hydrogel, single vision contact lens worn in one eye in a daily wear modality for approximately 5 days or more per week, at least 10 hours per day, for up to 4 weeks.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Balafilcon A contact lens (PureVision® 2)
Description: Silicone hydrogel, single vision contact lens worn in one eye in a daily wear modality for approximately 5 days or more per week, at least 10 hours per day, for up to 4 weeks.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Contact lens solution (Clear Care®)
Description: Hydrogen peroxide-based system used for cleaning, disinfection and overnight storage of the study contact lenses.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Contact lens solution (Clear Care®)
Description: Hydrogen peroxide-based system used for cleaning, disinfection and overnight storage of the study contact lenses.
Study: NCT01690988

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine (0.5 mg/kg)
Description: Low dose (sub-anesthetic) 0.5 mg/kg ketamine following induction of anesthesia or administration of sedative medications.
Study: NCT01607307

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oral/enteral placebo solution
Description: Oral placebo solution (5 g tid, 15 g/day) given immediately before meals or every 8 h from preoperative day 3 to postoperative day 7 for 10 consecutive days. A diluent placebo solution given immediately after surgery and on postoperative day 1 via Argyle enteral feeding tube (10 Fr), which terminates in the jejunum to prevent aspiration pneumonia.
Study: NCT01690988

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline (placebo)
Description: Normal saline IV following induction of anesthesia or administration of sedative medications

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine (1 mg/kg)
Description: Low dose (sub-anesthetic) 1 mg/kg ketamine following induction of anesthesia or administration of sedative medications.
Study: NCT05381389

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine Hydrochloride in-plane approach for the interscalene block
Description: 20 ml of 0.5% bupivacaine added to them 50 μg adrenaline in a concentration of 1:400,000, were prepared by an assistant immediately before administration and injected in an in-plane approach to the brachial plexues

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine Hydrochloride out of-plane approach for the interscalene block
Description: 20 ml of 0.5% bupivacaine added to them 50 μg adrenaline in a concentration of 1:400,000, were prepared by an assistant immediately before administration and injected in an out of-plane approach to the brachial plexues
Study: NCT02887365

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tegafur-uracil
Study: NCT02217683

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nitric Oxide
Description: Nitric oxide at 80 part per million will be administrated by inhalation for approximately 1 hour during the blood transfusion
Study: NCT02192619

Intervention type: OTHER
Intervention: observational
Study: NCT02304419

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Galunisertib
Description: Administered orally.
Study: NCT04097080

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NBTX-001
Description: Active drug group will receive 6 doses of NBTX-001 given three times a week.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Standard of Care
Description: Placebo group will receive reconstituted air given three times a week.
Study: NCT01608529

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Feel Breathe, restriction device ventilatory nasal
Description: The Feel Breathe (FB) consisted of a small adhesive strip that is placed across the bridge of the nose during exercise. The FB was place following procedures for placement as indicated by the manufacturer's directions, while the placebo nasal, was placed over the nostrils of the subject, without interfering nasal breathing; thus, nasal airflow resistance was not increase. Each subject was required to perform three identical submaximal exercises with intensity at 50% VT1-VT2 under different breathing conditions. The breathing conditions were: oronasal, nasal and FB breathing. All participants performed three trials of stable load (50% VT1-VT2) for 10 minutes in the three conditions mentioned above, setting the cadence at 70-75 rpm, and controlling the same in all three exercise conditions.
Study: NCT01983449

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone Sodium Phosphate Injection, USP
Description: Adventitial infusion of dexamethasone after angioplasty or atherectomy-based revascularization of the superficial femoral or popliteal artery.
Study: NCT02944734

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Candesartan Cilexetil 8mg
Description: Candesartan Cilexetil 8mg Daily oral administration for 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Candesartan Cilexetil 8mg
Description: Candesartan Cilexetil 8mg Daily oral administration for 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Candesartan Cilexetil 8mg
Description: Candesartan Cilexetil 8mg Daily oral administration for 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Candesartan Cilexetil 16mg
Description: Candesartan Cilexetil 16mg Daily oral administration for 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Candesartan Cilexetil 16mg
Description: Candesartan Cilexetil 16mg Daily oral administration for 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Candesartan Cilexetil 16mg
Description: Candesartan Cilexetil 16mg Daily oral administration for 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine 5mg
Description: Amlodipine 5mg Daily oral administration for 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine 5mg
Description: Amlodipine 5mg Daily oral administration for 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine 5mg
Description: Amlodipine 5mg Daily oral administration for 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine 10mg
Description: Amlodipine 10mg Daily oral administration for 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine 10mg
Description: Amlodipine 10mg Daily oral administration for 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine 10mg
Description: Amlodipine 10mg Daily oral administration for 8 weeks
Study: NCT02972281

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Immunological diagnosis tests
Description: (Non exhaustive list): hemogram, IgG, A, M, IgG subclasses, complement, vaccinal response to protein and polysaccharide antigens, ...
Study: NCT01188460

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-help manual for insomnia
Description: Implementation of chapters of self-help manual at home, and completion of sleep diary in terms of time in bed, hours of sleep, time to fall asleep, number of awakenings, and sleep quality

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Sleep diary

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep diary
Study: NCT04119388

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Adapted sports practices
Description: Adapted sports practices for 30 minutes twice a week
Study: NCT03661255

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PC CARES
Description: PC CARES trains local residents to deliver the PC CARES curriculum in their own community. These facilitators will attend a 40 hour training, and then will deliver the 4 session PC CARES curriculum in their home village. To aid local facilitators, each session follows the same structure after a beginning ritual:(1) agreements/safe talk, (2)'small wins', (3)'what do we know?' (facilitator shares current research on suicide prevention or wellness) (4)'what do we think?' (participants have an opportunity to discuss their thoughts on the research presented), and (5)'what we want to do?' (participants identify what steps they can take in their village to make positive change).The content of learning circles (LCs) includes community-level conditions, evidence-based approaches, risk and protective factors that can prevent suicide and promote well-being.Each LC includes both primary and secondary prevention strategies.Teaching tools include charts, short films, and case studies.
Study: NCT02518542

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic intervention A
Description: POEM: Per oral endoscopic myotomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic intervention B
Description: PRD: Prolonged dilatation by temporary implantation of large diameter stent . Stents are additionally attached to the esophageal wall by different technical options.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic intervention C
Description: Endoscopic balloon dilatation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic Surgery
Description: Laparoscopic Heller myotomy
Study: NCT00329784

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Peanut Consumption Group
Description: Peanut-containing snack. Children are to consume 2 g of peanut protein in three servings per week (total of 6 g) over 3 servings.
Study: NCT01916187

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imetelstat